Abstract
Desvenlafaxine (DES) and Alprazolam (ALP) are the drugs commonly prescribed together for the treatment of Major Depressive Disorders (MDD). A literature survey revealed, there is no method for the simultaneous determination of these two drugs. The purpose of this research was to develop and validate a simple, accurate, precise, robust, and isocratic RP–HPLC method for simultaneous determination of DES and ALP in human spiked plasma using UV-detector in short analysis time. The method utilized Hypersil BDS C18 (250 mm×4.6 mm, 5 μm) through an isocratic mode of elution using HPLC grade acetonitrile and 0.02M KH2PO4 buffer (65:35) and 0.1% Tri Fluoro Acetic acid (TFA) with pH 4.00 adjusted with 1M KOH. The flow rate was 1.00 mLmin-1 and elution of the drugs was monitored at 230nm. The elution time of DES and ALP was 4.011 and 5.182 minutes respectively. The method was linear for the concentration range 10–150 μgmL-1 for DES and 5.0–75.0 μgmL-1 for ALP. According to the validation results, the method is sensitive with Limit of Detection (LOD) 4.740 μgmL-1 and Limit of Quantification (LOQ) of 14.365 μgmL-1 for DES and LOD 1.891 μgmL-1 & LOQ 5.730 μgmL-1 for ALP. The reproducibility of results with minute deliberate variations in method parameters has proven that the method is robust. The data from stability studies show a non-significant change in drugs solutions for 2 months. The optimized method was validated as per International Conference for Harmonisation (ICH) Q2(R1) guidelines. This method can be used for the estimation of DES and ALP in plasma and can evaluate pharmacokinetic parameters of both drugs simultaneously.
Highlights
Depression refers to a heterogeneous group of ailments varying in symptoms and in etiology
Simultaneous quantification of desvenlafaxine and alprazolam in human spiked plasma causes of disease burden as approximately 17% of the world population experiences an episode of Major Depressive Disorders (MDD) during lifetime [1,2,3]
This study describes validation parameters stated by International Conference for Harmonisation (ICH) Q2R1 guidelines [28] to ensure suitability, accuracy, reliability as well as the feasibility of the developed method
Summary
Depression refers to a heterogeneous group of ailments varying in symptoms and in etiology. It may express itself either as major depressive disorder or a minor disease with a collection of physical as well as mental depressive symptoms. In 2015, WHO estimated that 4.4% of the global population is affected with depression but it is ranked 4th among global. Its prevalence rate peaks in old adulthood with >7.5% in females and >5.5% in males. It occurs in children and adolescents but at a lower rate as compared to adults [3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
